factual

Evergreening And Product Hopping Block Generics

Within Hatch-Waxman, companies practice evergreening and product hopping—making a minor modification to a drug's delivery, dosage, or form right as the patent expires, obtaining a new patent on the trivially changed version, and then withdrawing the old version so generics of the original cannot be substituted.

factualpending

Speaker

Robin Feldman

Evidence Quote

“you try to make a minor modification to the drug's delivery or dosage or something else related to the system and then get a new patent on this new version”

Source

Robin Feldman on Drug Patents, Generics, and Drug Wars— EconTalk
Created: 6/13/2026, 12:11:23 AM

Your notes

Loading notes...